Alimera Sciences resubmits New Medication Application for ILUVIEN Alimera Sciences.

At this right time, Alimera awaits the FDA's acceptance of the resubmission and a Prescription Medication User Fee Act day. Alimera intends to provide that info when it becomes available. Related StoriesTARSA Therapeutics' TBRIA NDA approved by FDA for reviewMylan announces U.S. Launch of generic Fusilev for InjectionMylan announces U.S. Launch of generic AXERT tablets In the resubmission, Alimera responded to questions raised in the FDA's October 2013 complete response letter and provided a safety update, which included commercial encounter with ILUVIEN in European countries. We are pleased to resubmit ILUVIEN for approval in the usa, stated Dan Myers, Alimera's president and chief executive officer. We look forward to an acknowledgment from the FDA that the response is usually complete and that a PDUFA date has been confirmed.June Last, Stryker Corp. Recalled specific hip implant products because of corrosion and other complications. Last month, another device maker, Biomet, agreed to pay at least $200,000 each to a huge selection of people who received artificial hips which were later replaced. And in November, Johnson & Johnson decided to pay $2.5 billion to settle 8 roughly,000 sufferers’ lawsuits over an all-metal hip implant it pulled from the market in 2010 2010. Even good implants can fail as time passes – about 1 % or fewer fail each whole year. After 10 years, more than 90 % of them are still functioning, Jacobs and Berry said.